Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis.
Autoimmune
COVID-19
Efficacy
Immunocompromised patient
Malignancy
SARS-CoV-2
Transplantation
Vaccination
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
08 08 2022
08 08 2022
Historique:
received:
29
11
2021
accepted:
18
07
2022
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
11
8
2022
Statut:
epublish
Résumé
Immunocompromised (IC) patients are at higher risk of more severe COVID-19 infections than the general population. Special considerations should be dedicated to such patients. We aimed to investigate the efficacy of COVID-19 vaccines based on the vaccine type and etiology as well as the necessity of booster dose in this high-risk population. We searched PubMed, Web of Science, and Scopus databases for observational studies published between June 1st, 2020, and September 1st, 2021, which investigated the seroconversion after COVID-19 vaccine administration in adult patients with IC conditions. For investigation of sources of heterogeneity, subgroup analysis and sensitivity analysis were conducted. Statistical analysis was performed using R software. According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses, we included 81 articles in the meta-analysis. The overall crude prevalence of seroconversion after the first (n: 7460), second (n: 13,181), and third (n: 909, all population were transplant patients with mRNA vaccine administration) dose administration was 26.17% (95% CI 19.01%, 33.99%, I The rising pattern of seroconversion after boosting tends to be promising. In this case, more attention should be devoted to transplant patients who possess the lowest response rate.
Sections du résumé
BACKGROUND
Immunocompromised (IC) patients are at higher risk of more severe COVID-19 infections than the general population. Special considerations should be dedicated to such patients. We aimed to investigate the efficacy of COVID-19 vaccines based on the vaccine type and etiology as well as the necessity of booster dose in this high-risk population.
MATERIALS AND METHODS
We searched PubMed, Web of Science, and Scopus databases for observational studies published between June 1st, 2020, and September 1st, 2021, which investigated the seroconversion after COVID-19 vaccine administration in adult patients with IC conditions. For investigation of sources of heterogeneity, subgroup analysis and sensitivity analysis were conducted. Statistical analysis was performed using R software.
RESULTS
According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses, we included 81 articles in the meta-analysis. The overall crude prevalence of seroconversion after the first (n: 7460), second (n: 13,181), and third (n: 909, all population were transplant patients with mRNA vaccine administration) dose administration was 26.17% (95% CI 19.01%, 33.99%, I
CONCLUSION
The rising pattern of seroconversion after boosting tends to be promising. In this case, more attention should be devoted to transplant patients who possess the lowest response rate.
Identifiants
pubmed: 35941646
doi: 10.1186/s12985-022-01858-3
pii: 10.1186/s12985-022-01858-3
pmc: PMC9358061
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Vaccines, Synthetic
0
mRNA Vaccines
0
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
132Informations de copyright
© 2022. The Author(s).
Références
Am J Transplant. 2021 Aug;21(8):2913-2915
pubmed: 33864722
J Clin Invest. 2021 Jul 15;131(14):
pubmed: 34101623
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Eur J Med Res. 2022 Feb 12;27(1):23
pubmed: 35151362
Infect Dis Rep. 2021 Oct 28;13(4):924-929
pubmed: 34842753
Blood Cancer J. 2021 Aug 10;11(8):142
pubmed: 34376633
Vaccines (Basel). 2021 Jul 04;9(7):
pubmed: 34358154
J Heart Lung Transplant. 2021 Aug;40(8):759-762
pubmed: 34034958
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
Transplantation. 2021 Nov 1;105(11):e226-e233
pubmed: 34381004
Future Oncol. 2021 Nov;17(33):4447-4456
pubmed: 34342517
Lancet Gastroenterol Hepatol. 2022 Apr;7(4):342-352
pubmed: 35123676
Sci Immunol. 2021 Jun 15;6(60):
pubmed: 34131023
JAMA Oncol. 2021 Oct 1;7(10):1507-1513
pubmed: 34236381
Transplantation. 2021 Nov 1;105(11):e259-e260
pubmed: 34387243
Lancet Rheumatol. 2021 Nov;3(11):e778-e788
pubmed: 34396154
Lancet Reg Health Eur. 2021 Oct;9:100178
pubmed: 34318288
JAMA Netw Open. 2021 Feb 1;4(2):e2037069
pubmed: 33533933
Transplantation. 2021 Aug 1;105(8):e82-e83
pubmed: 34098566
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Crohns Colitis. 2022 Feb 23;16(2):251-258
pubmed: 34379729
Eur Radiol. 2021 Jul;31(7):5178-5188
pubmed: 33449185
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
Ann Rheum Dis. 2021 Oct;80(10):1351-1352
pubmed: 34031032
Ann Rheum Dis. 2021 Oct;80(10):1317-1321
pubmed: 34144967
Am J Transplant. 2021 Dec;21(12):3990-4002
pubmed: 34453872
Cancers (Basel). 2021 Aug 20;13(16):
pubmed: 34439346
Transplantation. 2021 Nov 1;105(11):e267-e269
pubmed: 34342963
JAMA. 2021 Jul 23;:
pubmed: 34297036
Clin Microbiol Infect. 2021 Aug;27(8):1173.e1-1173.e4
pubmed: 33957273
JAMA Oncol. 2021 Aug 1;7(8):1133-1140
pubmed: 34047765
Transplantation. 2021 Jul 1;105(7):e72-e73
pubmed: 33741844
Am J Transplant. 2022 Jan;22(1):322-323
pubmed: 34331842
Am J Transplant. 2021 Dec;21(12):3980-3989
pubmed: 34347934
Ann Rheum Dis. 2021 Oct;80(10):1322-1329
pubmed: 34362747
Ann Rheum Dis. 2021 Oct;80(10):1365-1366
pubmed: 34429320
Lancet Gastroenterol Hepatol. 2022 Apr;7(4):280-282
pubmed: 35123675
Clin Infect Dis. 2021 Jan 27;72(2):340-350
pubmed: 33501974
Open Forum Infect Dis. 2021 Jun 30;8(7):ofab353
pubmed: 34337100
J Hematol Oncol. 2021 May 17;14(1):81
pubmed: 34001183
Clin Infect Dis. 2021 Sep 15;73(6):e1397-e1401
pubmed: 33949644
Int Immunopharmacol. 2021 Oct;99:108021
pubmed: 34352567
Leukemia. 2021 Dec;35(12):3573-3577
pubmed: 34023850
J Allergy Clin Immunol. 2021 Sep;148(3):739-749
pubmed: 34087242
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
Transplantation. 2021 Nov 1;105(11):e270-e271
pubmed: 34284420
J Am Soc Nephrol. 2021 Sep;32(9):2147-2152
pubmed: 34112706
Res Synth Methods. 2010 Apr;1(2):97-111
pubmed: 26061376
J Intern Med. 2021 Dec;290(6):1264-1267
pubmed: 34237179
Ann Rheum Dis. 2021 Oct;80(10):1330-1338
pubmed: 34127481
Am J Transplant. 2021 Aug;21(8):2727-2739
pubmed: 34036720
Transplantation. 2021 Sep 1;105(9):e94-e95
pubmed: 33831941
Cancers (Basel). 2021 Jul 28;13(15):
pubmed: 34359701
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Rheumatol Int. 2021 Aug;41(8):1429-1440
pubmed: 34109466
Nat Med. 2021 Oct;27(10):1744-1751
pubmed: 34331051
Eur J Heart Fail. 2021 Sep;23(9):1555-1559
pubmed: 33963635
Crit Rev Clin Lab Sci. 2020 Sep;57(6):365-388
pubmed: 32645276
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
JAMA Oncol. 2021 Nov 1;7(11):1716-1718
pubmed: 34379092
Liver Transpl. 2021 Dec;27(12):1852-1856
pubmed: 34407309
Cancer Cell. 2021 Aug 9;39(8):1034-1036
pubmed: 34348121
Virol J. 2021 Nov 18;18(1):225
pubmed: 34794467
Transplantation. 2021 Nov 1;105(11):e234-e243
pubmed: 34310101
Am J Transplant. 2021 Dec;21(12):4043-4051
pubmed: 34431207
Ann Oncol. 2021 Aug;32(8):1051-1053
pubmed: 33932501
Am J Transplant. 2021 Dec;21(12):3971-3979
pubmed: 34291552
J Geriatr Oncol. 2021 Nov;12(8):1253-1255
pubmed: 34175246
Vaccines (Basel). 2021 Jun 30;9(7):
pubmed: 34208884
EJHaem. 2021 Jun 01;2(3):520-524
pubmed: 34226903
Am J Hematol. 2021 Oct 1;96(10):1195-1203
pubmed: 34185336
Transplantation. 2021 Sep 1;105(9):2119-2123
pubmed: 34028386
ACR Open Rheumatol. 2021 Sep;3(9):622-628
pubmed: 34273260
Nat Rev Nephrol. 2021 Dec;17(12):785-787
pubmed: 34580488
Viruses. 2021 Apr 25;13(5):
pubmed: 33923063
Am J Transplant. 2021 Aug;21(8):2719-2726
pubmed: 33866672
Lancet. 2021 Jan 9;397(10269):72-74
pubmed: 33306990
Ann Rheum Dis. 2021 Aug;80(8):1098-1099
pubmed: 33757968
Clin Res Cardiol. 2021 Aug;110(8):1142-1149
pubmed: 34241676
Kidney Int. 2021 Jun;99(6):1487-1489
pubmed: 33775674
Ann Rheum Dis. 2021 Oct;80(10):1306-1311
pubmed: 33762264
Clin Exp Med. 2022 May;22(2):319-323
pubmed: 34283338
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Ann Intern Med. 2021 Sep;174(9):1330-1332
pubmed: 34125572
Am J Transplant. 2021 Nov;21(11):3806-3807
pubmed: 34153162
Clin Chem. 2021 Dec 30;68(1):251-253
pubmed: 34358295
J Am Soc Nephrol. 2021 Sep;32(9):2153-2158
pubmed: 34135083
JAMA. 2021 May 4;325(17):1784-1786
pubmed: 33720292
Transplant Cell Ther. 2021 Oct;27(10):880.e1-880.e4
pubmed: 34293520
Ann Rheum Dis. 2022 Feb;81(2):295-296
pubmed: 34635493
J Heart Lung Transplant. 2021 Aug;40(8):754-758
pubmed: 34120839
Kidney Int. 2021 Jun;99(6):1498-1500
pubmed: 33887315
Clin Rheumatol. 2021 Feb;40(2):797-798
pubmed: 33426632
Clin Infect Dis. 2022 Mar 23;74(6):1093-1096
pubmed: 34166499
Gut. 2021 Oct;70(10):1884-1893
pubmed: 33903149
J Hepatol. 2021 Aug;75(2):435-438
pubmed: 33892006
Transpl Int. 2014 Feb;27(2):197-203
pubmed: 24289658
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Infect Disord Drug Targets. 2022;22(2):e230921196758
pubmed: 34554905
Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3540-3549
pubmed: 33966088
J Hematol Oncol. 2021 May 31;14(1):86
pubmed: 34059088
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2
pubmed: 34133951
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Blood Cancer J. 2021 Aug 2;11(8):138
pubmed: 34341335